Skip to search formSkip to main contentSkip to account menu

deferasirox

Known as: deferasirox [Chemical/Ingredient], 4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid, 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid 
A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (3)

BenzoatesIron Chelating AgentsTriazoles

Narrower (2)

ExjadeICL 670
Iron Chelating Activity [MoA]deferasirox 125 MG Tablet for Oral Suspension [Exjade]deferasirox 360 MG Oral Tablet [Jadenu]deferasirox Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron
ABSTRACT Differences in deferasirox susceptibility among members of the order Mucorales are unknown. Here we show that… 
2010
2010
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
Iron plays a major role in the growth and virulence of ferrophilic organisms like Vibrio vulnificus. People who reside in the… 
Highly Cited
2009
Highly Cited
2009
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
This subgroup analysis evaluated the effect of once‐daily oral deferasirox on labile plasma iron (LPI) levels in patients from… 
2009
2009
Myelodysplasia paranoia: iron as the new radon.
2008
2008
Acute interstitial nephritis due to deferasirox: a case report.
Deferasirox is a new oral iron chelator used to treat transfusional iron overload. Pre-marketing clinical trials revealed little… 
Review
2008
Review
2008
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
Background: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant… 
Highly Cited
2007
Highly Cited
2007
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
BACKGROUND Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron… 
Highly Cited
2007
Highly Cited
2007
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
Transfusional iron overload in patients with chronic anemias can result in multiple organ failure. Experience in the management… 
2006
2006
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
BACKGROUND AND OBJECTIVES: Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic… 
2005
2005
Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).
ICL670 (deferasirox) is an orally active iron chelator, intended as once daily mono-therapy for the treatment of transfusional… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)